IO Biotech Inc
IOBT2.150USD
-0.070-3.15%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
141.64MMarket Cap
LossP/E TTM
More Details of IO Biotech Inc Company
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Company Info
Ticker SymbolIOBT
Company nameIO Biotech Inc
IPO dateNov 05, 2021
CEODr. Mai-Britt Zocca, Ph.D.
Number of employees80
Security typeOrdinary Share
Fiscal year-endNov 05
AddressOle Maaloes Veh 3
CityCOPENHAGEN
Stock exchangeNASDAQ Global Select Consolidated
CountryDenmark
Postal code2200
Phone4570702980
Websitehttps://www.iobiotech.com/
Ticker SymbolIOBT
IPO dateNov 05, 2021
CEODr. Mai-Britt Zocca, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Chief Accounting Officer, Vice President - Finance
Chief Accounting Officer, Vice President - Finance
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Dr. Faical Miyara, Ph.D.
Dr. Faical Miyara, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Chief Accounting Officer, Vice President - Finance
Chief Accounting Officer, Vice President - Finance
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 22
Updated: Thu, May 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lundbeckfond Ventures
21.18%
Kurma Partners SA
10.35%
Vivo Capital, LLC
9.37%
HBM Partners AG
5.99%
Novo Holdings A/S
5.09%
Other
48.02%
Shareholders
Shareholders
Proportion
Lundbeckfond Ventures
21.18%
Kurma Partners SA
10.35%
Vivo Capital, LLC
9.37%
HBM Partners AG
5.99%
Novo Holdings A/S
5.09%
Other
48.02%
Shareholder Types
Shareholders
Proportion
Venture Capital
47.38%
Investment Advisor
8.35%
Hedge Fund
4.71%
Investment Advisor/Hedge Fund
3.44%
Research Firm
2.54%
Individual Investor
0.36%
Other
33.21%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
52
44.00M
66.79%
-12.23M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
2023Q2
46
22.57M
78.34%
-5.75M
2023Q1
42
24.23M
84.91%
+7.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lundbeckfond Ventures
13.95M
21.18%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
10.35%
--
--
Apr 11, 2025
Vivo Capital, LLC
6.17M
9.37%
--
--
Apr 11, 2025
HBM Partners AG
3.94M
5.99%
--
--
Apr 11, 2025
Novo Holdings A/S
3.35M
5.09%
--
--
Mar 31, 2025
PFM Health Sciences, LP
2.34M
3.55%
--
--
Mar 31, 2025
Marshall Wace LLP
2.11M
3.2%
--
--
Mar 31, 2025
BofA Global Research (US)
1.65M
2.51%
--
--
Mar 31, 2025
Pivotal Bioventure Partners Investment Advisor LLC
864.20K
1.31%
--
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
789.46K
1.2%
-69.71K
-8.11%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
